Healthcare Industry News: multidrug resistant
News Release - June 27, 2012
Kedem Pharmaceuticals to Appoint New Chief Operating OfficerVANCOUVER, BRITISH COLUMBIA--(Healthcare Sales & Marketing Network)- Kedem Pharmaceuticals Inc. (KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that the company has promoted its Senior Vice President, Dr. Lola Maksumova to the position of Chief Operating Officer (COO).
"Over the past several months, Lola's increasing role in the process manufacturing, clinical program development and day-to-day operational leadership has been critical to the success of company's lead products," said Dr. Hassan Salari, Chairman and CEO. "As Chief Operating Officer, Lola's strong oversight of the company's operational aspects and clinical assets development will continue to drive the advancement and execution of company's drug development milestones."
About Dr. Maksumova
Dr. Maksumova joined Kedem Pharmaceuticals in 2011. She has brought over two decades of highly professional experience in drug research and product development across a spectrum of therapeutic indications ranging from pulmonary fibrosis to multidrug resistant leukaemia. Dr. Maksumova has proven herself as a solid and knowledgeable expert in drug formulation strategies, clinical trial management and various regulatory approaches to the successful drug approval process. Prior to Kedem Pharmaceuticals Dr. Maksumova worked as a Vice President Drug Development for Pacific Therapeutics.
Dr. Maksumova received her MD from Tashkent Medical School (Uzbekistan) and PhD in Medical Biochemistry from Hamamatsu University School of Medicine (Shizuoka, Japan), followed by post-doctoral training at Virginia Mason Medical Research Centre (Seattle, USA) and Department of Medicine at University of British Columbia (Vancouver, Canada).
About Kedem Pharmaceuticals Inc. KDMP.OB
A specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for osteoporosis, sleeping disorders, pain killers, migraine, anti-allergy medications, cardiovascular diseases, lung medications, and addiction replacement therapies. For more information visit: www.kedempharmaceuticals.com
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Additionally this press release include statement within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to high risks, uncertainties and other factors, including that the Regulatory Agencies may not agree to the claims made in the Company documents related to our products, and product development. There are risks that due to unforeseen reasons, matters could cause the actual results to differ materially from those referred in our fillings. Risks involved patent infringement, trademark and other commercially related actions that hinder the product development and marketing. Additional risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission, as well as to obtain independent third party opinions before investing in the Company's securities.
Source: Kedem Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.